Next-generation SUSTAINABLE quillaja saponins for pharmaceuticals

Q-VANT has addressed the QS-21 adjuvant volume supply problem and quality obstacles for vaccine developers via a highly disruptive and proprietary technology platform.

About Us

Q-VANT Biosciences is a privately-held company that has solved the supply chain problem of QS-21 and other quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets.

The company’s disruptive technology increases the potential for sustainable QS-21 supply by a factor of 1,000 resulting in a possible annual production capacity exceeding 20 billion pharmaceutical doses.

Executive Team

Doug Klaiber

Doug Klaiber

Chief Executive Officer

More than 25 years of start-up, technology and pharmaceutical experience. Former CEO of Decas Botanical Synergies and Naturex-DBS.

Bruce Forrest, MD & MBA

Bruce Forrest, MD & MBA

Chief Scientific Officer

Former SVP R&D Pfizer/Wyeth Vaccines. More than 25 years of experience in vaccine & adjuvant  development and commercialization.

Hans Konsens

Hans Konsens

Chief Operating Officer

More than 10 years of experience in quillaja extract process development, supply chain, manufacturing, R&D and commercialization. Former Founder and Managing Director of Chile Botanics–Naturex, global leader in the Quillaja Extracts markets.

Jack Love, Ph.D.

Jack Love, Ph.D.

VP of Regulatory Affairs

Former AVP Regulatory Affairs for Pfizer Vaccines. More than 25 years of pharmaceutical experience including new vaccine development and regulatory approvals.

Juan José Albarrán

Juan José Albarrán

Chief Commercial Officer

More than 10 years of experience in quillaja extract process development, supply chain, manufacturing, R&D and commercialization. Former Founder and Managing Director of Chile Botanics–Naturex, global leader in the Quillaja Extracts markets.

Stein Lokstad

Stein Lokstad

VP of Business Development

Former GM of Brenntag Biosector vaccine adjuvant company. More than 25 years pharmaceutical experience including 10 years developing and selling vaccine adjuvants.

Operations

Matthieu Privat

Matthieu Privat

Business Development Manager

More than 10 years of experience in molecular biology and quillaja saponin marketing, supply chain. Former Deputy Commercial Manager of Desert King.

Vannia Delgado

Vannia Delgado

Quality & Regulatory Manager

More than 10 years of experience in quality management in the pharmaceutical industry.

Scientific Team

Elias Atala, Ph.D.

Elias Atala, Ph.D.

Technology Manager

Expert in chromatographic process development with 10 years of experience in R&D chemistry, purification and application of quillaja saponins.

Francisco Ibañez, Ph.D.

Francisco Ibañez, Ph.D.

Vaccine and Adjuvant Specialist Developer

Biochemist specialized in immunology with vast academic and professional experience in the development of antiviral drugs, vaccines against respiratory viruses, and adjuvants.

Cristobal Silva

Cristobal Silva

R&D Specialist

R&D expert in the industrial field of botanical extracts including purification, analytical quantification and product formulation.